The trial will assess the safety, pharmacokinetics, pharmacodynamics and efficacy of VYN202 in treating immuno-inflammatory conditions. Credit: Gorodenkoff / Shutterstock.

US-based biopharmaceutical company VYNE Therapeutics has received US Food and Drug Administration clearance for its investigational new drug (IND) application for VYN202, allowing it to begin a Phase Ia clinical trial.

The double-blind, placebo-controlled, first-in-human trial will assess VYN202’s safety, pharmacokinetics, pharmacodynamics and efficacy in both single ascending-dose (SAD) and multiple ascending-dose (MAD) portions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

VYN202 is a selective bromodomain and extra-terminal domain (BET) inhibitor designed for treating immuno-inflammatory conditions.

Around 64 healthy adult participants will be enrolled across five SAD and three MAD cohorts in the study.

If the Phase Ia segment is successful, VYNE will advance the drug to Phase Ib trials in individuals suffering from moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis.

See Also:

The company expects to report top-line results from the SAD/MAD trial in the second half of this year, with further results expected in the second half of next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

VYN202 is an oral small molecule designed for high selectivity (BD2 vs BD1), potent BD2 inhibition and optimal oral bioavailability.

VYNE believes that by focusing on BD2 selectivity, the drug could offer a convenient, non-biologic treatment for acute and chronic management of immuno-inflammatory diseases, where uncontrolled inflammatory signalling is prevalent.

VYNE Therapeutics president and CEO David Domzalski said: “VYN202 is a highly selective and potent orally administered BET inhibitor that we believe has significant potential as a treatment option for autoimmune diseases.

“Clearance of the IND for VYN202 marks a major step forward in this effort.

“We look forward to initiating the Phase Ia trial in the coming weeks to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.”

Last year, Tay Therapeutics and VYNE Therapeutics signed a licensing deal for the development of VYN202 as a possible treatment for immune-inflammatory and fibrotic disorders.

The drug has previously shown the potential to cause anti-inflammatory and anti-fibrotic effects in preclinical models.